Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies

NCT01154426 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01154426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01154426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
October 31, 2013
Enrollment
31 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, brca1 mutation carrier, brca2 mutation carrier